Skip to search formSkip to main contentSkip to account menu

Refractory B-Cell Non-Hodgkin Lymphoma

Known as: B-Cell Lymphoma Refractory, Refractory B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin's Lymphoma 
B-cell non-Hodgkin lymphoma that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

12 relations
Atypical lymphocyteB-LymphocytesHematopoietic and Lymphoid CellHematopoietic and Lymphoid Tissue

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma Jeffrey Wang, Jacqueline Wang, Elyse Lopez… 
2018
2018
Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.
e19550Background: Ibrutinib (Ibru) has shown therapeutic activity in patients (pts) with various B-cells malignancies, making it… 
2017
2017
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
2015
2015
Host immunity dictates influenza A(H1N1)pdm09 infection outcome in hematology–oncology patients
Host immunity dictates influenza A(H1N1)pdm09 infection outcome in hematology–oncology patients 
Review
2014
Review
2014
Clinical Translational Research of Chimeric Antigen Receptor-T (CAR-T) Cells for the Treatment of Relapsed and Refractory B-cell Lymphoma/Leukemia——Review
2013
2013
Rituximab used in three cases with relapsed non-Hodgkin's lymphoma.
Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been… 
2013
2013
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell…
Patients with B cell malignancies refractory to allogeneic stem cell transplantation (SCT) can be treated by subsequent… 
2011
2011
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy
The treatment outcomes for B-cell non-Hodgkin lymphoma have improved since targeted agents such as rituximab were incorporated… 
Review
2003
Review
2003
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
OBJECTIVE Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900… 
2000
2000
Salvage Therapy for Relapsed Mediastinal B-Cell Lymphoma with Allogeneic HLA-Identical Related Donor Bone Marrow Transplantation, Donor Lymphocyte Infusion and IDEC-C2B8
Primary B-cell lymphoma of the mediastinum is an aggressive non-Hodgkin's lymphoma with distinct clinicopathologic features… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)